Profiel
Paul F.
Howley worked as a Research Director at Bavarian Nordic A from 1998 to 2002.
He then worked as a Technical Director at Prescient Therapeutics Ltd.
from 2002 to 2008.
After that, he worked as a Director of Virology & Protein Chemistry at Sentinext Therapeutics Sdn.
Bhd.
Dr. Howley received his undergraduate degree from The University of Reading in 1985.
Eerdere bekende functies van Paul F. Howley
| Bedrijven | Functie | Einde |
|---|---|---|
| PRESCIENT THERAPEUTICS LIMITED | Hoofd Techniek/Wetenschap/O&O | 01-01-2008 |
| BAVARIAN NORDIC A/S | Hoofd Techniek/Wetenschap/O&O | 01-01-2002 |
Sentinext Therapeutics Sdn. Bhd.
 Sentinext Therapeutics Sdn. Bhd. BiotechnologyHealth Technology Sentinext Therapeutics Sdn. Bhd. develops vaccines and therapeutics for tropical infectious diseases. Its pharmaceutical research and development focuses on EV71, polio, influenza and dengue diseases. The company was founded by Mary Jane Cardosa and Peter Samuel Wulff in 2009 and is headquartered in Penang, Malaysia. | Corporate Officer/Principal | - |
Opleiding van Paul F. Howley
| The University of Reading | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BAVARIAN NORDIC A/S | Health Technology |
| PRESCIENT THERAPEUTICS LIMITED | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Sentinext Therapeutics Sdn. Bhd.
Sentinext Therapeutics Sdn. Bhd. BiotechnologyHealth Technology Sentinext Therapeutics Sdn. Bhd. develops vaccines and therapeutics for tropical infectious diseases. Its pharmaceutical research and development focuses on EV71, polio, influenza and dengue diseases. The company was founded by Mary Jane Cardosa and Peter Samuel Wulff in 2009 and is headquartered in Penang, Malaysia. | Health Technology |